Rapid Benzodiazepine Detoxification Using Flumazenil - 1
NCT00000246 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10
Last updated 2016-09-08
Summary
The purpose of this study is to verify the hypothesis that the benzodiazepine antagonist, flumazenil, will reduce acute benzodiazepine withdrawal.
Conditions
- Substance-Related Disorders
Interventions
- DRUG
-
Flumazenil
Sponsors & Collaborators
-
National Institute on Drug Abuse (NIDA)
collaborator NIH -
Yale University
lead OTHER
Principal Investigators
-
Scott Woods, M.D. · Yale University
Study Design
- Purpose
- TREATMENT
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 1993-01-31
- Primary Completion
- 1994-12-31
- Completion
- 1994-12-31
Countries
- United States
Study Locations
More Related Trials
-
Brief Motivational Intervention (BMI) on the Deprescription of Benzodiazepines and Related Substances in Adult Chronic Drug Users
NCT06446349 ·Status: RECRUITING ·Phase: NA
-
Acute Agitation in Emergency Psychiatry
NCT06752616 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Effects of Intranasal Oxytocin in the Treatment of Benzodiazepine Withdrawal: A Pilot RCT
NCT06757517 ·Status: RECRUITING ·Phase: PHASE2
-
Positron Emission Tomography (PET) Study With (11C)Flumazenil to Determine Central GABAA Receptor Occupancy of AZD7325
NCT00681720 ·Status: COMPLETED ·Phase: PHASE1
-
Dose Escalation Study of Intravenous Baclofen in Healthy Adult Volunteers
NCT01931319 ·Status: COMPLETED ·Phase: PHASE1
-
Multimodal Educative Data Feedback for Deprescribing BZD and Related Drugs in Outpatients: a Cluster RCT
NCT05859555 ·Status: COMPLETED ·Phase: NA
-
A Study to Examine the Distribution of PF-06372865 in the Brain of Healthy Volunteers Using Positron Emission Tomography and a Radioactive Tracer Following Oral Administration of One Dose of PF-06372865
NCT02138500 ·Status: COMPLETED ·Phase: PHASE1
-
Oral Remimazolam With and Without Alcohol in Healthy Female Subjects
NCT04113343 ·Status: COMPLETED ·Phase: PHASE1
-
Double Blind Placebo Control Opipramol-Baclofen Treatment for Addiction
NCT03065998 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Impact of Long Term of Benzodiazepine Use on Psychiatric Manifestation
NCT04792658 ·Status: UNKNOWN
-
Spectroscopic Imaging at 4T: A Drug Challenge Study
NCT01577706 ·Status: TERMINATED ·Phase: NA
-
Baclofen Effects on Marijuana Dependence
NCT02011516 ·Status: COMPLETED ·Phase: PHASE2
-
Psychopharmacological Treatment of Emotional Distress
NCT06133114 ·Status: RECRUITING ·Phase: PHASE4
-
BXCL501 After Stress to Increase Recovery Success
NCT06943404 ·Status: RECRUITING ·Phase: PHASE2
-
Ph1 Marinol Interaction Study - Part 2 - 1
NCT00490269 ·Status: COMPLETED ·Phase: PHASE1
-
Clonidine vs. Dexmedetomidine in Agitated Delirium in Intensive Care Patients
NCT04758936 ·Status: UNKNOWN ·Phase: PHASE4
-
Effect of Ketamine on Laboratory-induced Stress in Healthy Subjects
NCT04173962 ·Status: COMPLETED ·Phase: PHASE2
-
Role of Instructions in Nitrous Oxide Effects and Choice - 10
NCT00000258 ·Status: COMPLETED ·Phase: NA
-
Reinforcing Effects of Brief Exposures to Nitrous Oxide - 8
NCT00000256 ·Status: COMPLETED ·Phase: NA
-
The Effects of ∆-9-THC and Naloxone in Humans
NCT01591629 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
PROfylactic Haloperidol in Patients Defined as High Risk for DElirium With Delirium Risk mOdel
NCT03199950 ·Status: UNKNOWN ·Phase: PHASE4
-
Neurobiology of Opioid Dependence: 1 - 1
NCT00000192 ·Status: WITHDRAWN ·Phase: PHASE2
-
Study to Evaluate the Abuse Potential of ACT-541468 in Healthy Recreational Drug Users
NCT03657355 ·Status: COMPLETED ·Phase: PHASE1
-
Validation of the Drug Impaired Driving Scenario (DIDS) on the CRCDS-miniSim
NCT04970342 ·Status: COMPLETED ·Phase: PHASE1
-
Pilot Study 1: Efficacy and Safety of Sublingual Dexmedetomidine (BXCL501) for the Treatment of Agitation in the Emergency Department
NCT05974527 ·Status: WITHDRAWN ·Phase: PHASE4